Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rassool

Showing results (171-180 of 222) with videos related to

Pageof 23
Sort By:
Communications Medicine|June 9, 2026
Deep learning approach for probabilistic pulmonary function estimation from chest X-ray and peak expiratory flow rateChristoph Killing, Maximilian Wekerle, Jayne S Sutherland, et al.
Pathogens & Immunity|July 25, 2017
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS TrialPablo F Belaunzarán-Zamudio, Livio Azzoni, David H Canaday, et al.
Basic Life Sciences|January 1, 1990
Clinical studies of total body nitrogen in an Australian hospitalD B Stroud, D J Borovnicar, J R Lambert, et al.
Plos One|February 4, 2022
Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trialRobert S Wallis, Sibuse Ginindza, Trevor Beattie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2018
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA MutationsNicholas Pulliam, Fang Fang, Ali R Ozes, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2019
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiationRachel Abbotts, Michael J Topper, Christopher Biondi, et al.
The Lancet. Infectious Diseases|May 29, 2026
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trialRodney Dawson, Andreas H Diacon, Ebrahim Variava, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 12, 2020
Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiencyLena J McLaughlin, Lora Stojanovic, Aksinija A Kogan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialPedro Cahn, Paul E Sax, Kathleen Squires, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid LeukemiaMaria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Pageof 23

Showing results (171-180 of 222) with videos related to

Sort By:
Pageof 23
Communications Medicine|June 9, 2026
Deep learning approach for probabilistic pulmonary function estimation from chest X-ray and peak expiratory flow rateChristoph Killing, Maximilian Wekerle, Jayne S Sutherland, et al.
Pathogens & Immunity|July 25, 2017
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS TrialPablo F Belaunzarán-Zamudio, Livio Azzoni, David H Canaday, et al.
Basic Life Sciences|January 1, 1990
Clinical studies of total body nitrogen in an Australian hospitalD B Stroud, D J Borovnicar, J R Lambert, et al.
Plos One|February 4, 2022
Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trialRobert S Wallis, Sibuse Ginindza, Trevor Beattie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2018
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA MutationsNicholas Pulliam, Fang Fang, Ali R Ozes, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2019
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiationRachel Abbotts, Michael J Topper, Christopher Biondi, et al.
The Lancet. Infectious Diseases|May 29, 2026
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trialRodney Dawson, Andreas H Diacon, Ebrahim Variava, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 12, 2020
Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiencyLena J McLaughlin, Lora Stojanovic, Aksinija A Kogan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialPedro Cahn, Paul E Sax, Kathleen Squires, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid LeukemiaMaria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Pageof 23